KCA has funded a study to identify clinical and genetic markers which could be used to identify ALL patients at high-risk of treatment related toxicity. The overall goal is to facilitate future development of risk-adapted therapy for children with ALL, to reduce incidence of severe toxicities without reducing treatment efficacy; and improve quality of life for children and their families. A retrospective analysis of a large, homogenously treated Australian ALL cohort was used to identify both clinical and genetic markers for 3 severe treatment related toxicities (thrombosis, neurologic and bone toxicity).
Started: 1 July 2016
Ending: 30 June 2018
